Sloan-Kettering Institute For Cancer Research

Sloan-Kettering Institute For Cancer Research is a premier nonprofit cancer research institution located at 1275 York Ave, New York, NY, and is a subsidiary of Memorial Sloan Kettering Cancer Center. As a tax-exempt corporate entity registered in SAM.gov since February 25, 2002, the Institute serves as both a federal contract and grant prime awardee, conducting comprehensive cancer research and providing diagnostic and therapeutic innovations across multiple cancer types. The organization maintains an extensive portfolio of federally-funded research spanning basic science, translational research, clinical trials, and advanced therapeutic development aimed at advancing understanding of cancer mechanisms and improving patient outcomes.

Through federal contract awards, Sloan-Kettering Institute has demonstrated its capacity to deliver specialized research services and biological materials to the federal government. Most notably, the Institute received a $166,410.58 firm fixed-price purchase order from the National Cancer Institute for procuring 620 samples for the Multi-Ancestry Genome-Wide Association Study, with performance extending from September 2022 through September 2025. This contract, awarded without set-aside designation, exemplifies the Institute's role in providing critical biological specimens and research support for large-scale genomic studies. The organization's contract work has primarily been facilitated through the National Cancer Institute, reflecting the Institute's established relationships with federal cancer research agencies and its recognized expertise in providing high-quality research materials and services essential for advancing federal cancer research initiatives.

Sloan-Kettering Institute's federal grant portfolio is exceptionally extensive and diverse, encompassing numerous Project Grants and Cooperative Agreements totaling hundreds of millions of dollars across multiple funding agencies and programs. Primary funding sources include the National Cancer Institute (supporting research in cancer biology, treatment, detection, prevention, and cause research programs), the Defense Health Agency's Military Medical Research and Development program, the National Institute of Allergy and Infectious Diseases, the National Human Genome Research Institute, the National Institute of General Medical Sciences, the National Heart Lung and Blood Institute, the National Institute on Aging, the National Institute of Mental Health, the National Center for Complementary and Integrative Health, and the National Institute for Minority Health and Health Disparities. The Institute's research endeavors span cutting-edge scientific investigations including immunotherapy development (CAR-T cells, checkpoint inhibitors, bispecific antibodies), precision oncology and genomic profiling, metabolic mechanisms of cancer, tumor microenvironment characterization, novel therapeutic targets (antibody-drug conjugates, targeted radiotherapy), mechanistic studies of treatment resistance, clinical trials for rare and common malignancies, and health disparities research addressing underrepresented populations. Collaborative partnerships extend to numerous academic institutions and cancer centers including Columbia University, Weill Cornell Medical College, Duke University, University of Michigan, Northwestern University, Fred Hutchinson Cancer Center, Stanford University, and many others, enabling integrated multi-institutional research efforts. The Institute has also served as a sub-awardee on numerous grants where collaborating institutions serve as prime grantees, maintaining active roles in data coordination, specialized analyses, sample processing, and research implementation across diverse oncological and biomedical research domains.